Better Health for All

TELA Bio's core business is dedicated to soft-tissue reconstruction solutions, with products like OviTex and OviTex PRS designed to optimize clinical outcomes, leverage natural healing, and minimize exposure to permanent synthetic materials.

Clinical data from the BRAVO study showed a 24-month recurrence rate of 2.6% for OviTex in ventral hernias and statistically significant improvements in patient quality of life. The company has no revenue from products with significant negative health impacts. The company's Annual Report on Form 10-K includes a "Risk Factors" section for public disclosures. The company is subject to U.S. federal and state laws and foreign data protection laws, including GDPR, and its Code of Business Conduct and Ethics includes provisions for protecting employee medical information and patient data. The company's products aim to mitigate limitations of permanent synthetic mesh, which can cause chronic pain, infection, and compromised abdominal wall anatomy. The company provides employees and their families with access to health and wellness programs, including mental health support. The ovine rumen used in products is sourced from sheep raised for human consumption in New Zealand, inspected according to USDA approved standards, and processed in compliance with FDA regulations. The company educates surgeons on product value through conferences, symposia, direct training, webinars, and publishing clinical data. Clinical investigations are conducted under FDA's IDE regulations, requiring informed consent and adherence to protocols.

Fair Money & Economic Opportunity

TELA Bio, Inc. is a medical technology company focused on tissue reinforcement materials.

The company's core business does not involve lending, insuring, moving, or storing money for consumers or businesses. Therefore, the KPIs under the 'Fair Money & Economic Opportunity' value, which are designed for financial institutions, are not applicable to TELA Bio, Inc.

Fair Pay & Worker Respect

No specific, quantitative data points were found in the provided articles to assess TELA.US against the 'Fair Pay & Worker Respect' KPIs. While the company's Code of Business Conduct and Ethics (effective November 12, 2025) outlines policies for fair dealing, non-discrimination, equal opportunity, a safe and healthy work environment, and respect for employee rights under the National Labor Relations Act, these are policy statements and not measurable outcomes or statistics.

The articles do not provide information on living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage.

Fair Trade & Ethical Sourcing

TELA Bio reported zero substantiated child or forced labor incidents.

The company actively conducts due diligence and audits of existing raw materials suppliers, screens new suppliers, and performs extra due diligence on suppliers perceived to have a greater risk of modern slavery and human trafficking. TELA Bio performed its first Modern Day Slavery Assessment (MAST) on gov.co.uk, yielding a score of 92%.

Honest & Fair Business

TELA Bio has a Code of Business Conduct and Ethics, effective November 12, 2025, applicable to all employees, officers, and directors.

This code includes a policy of non-retaliation for good faith reporting of misconduct and provides multiple anonymous reporting channels, including a phone number and email. However, there is no evidence of independent investigation processes for these reports. The company's anti-corruption policy expects compliance with the Foreign Corrupt Practices Act and prohibits bribes, kickbacks, or similar payments. While an FCPA-compliant policy is in place, there is no information on the frequency or effectiveness metrics of related training. Aroa's facility, which manufactures OviTex products for TELA Bio, is FDA registered and ISO 13485 certified. This certification covers product quality and manufacturing, but there is no evidence of independent verification for broader ethical claims or company-wide compliance.

Kind to Animals

TELA Bio's products are primarily composed of animal-derived material, with over 95% biologic material sourced from ovine rumen (sheep forestomach).

Less than 5% of the product consists of polymer materials, indicating minimal substitution of animal inputs. The company relies entirely on non-human primate preclinical studies for product development, having used more than 200 non-human primates in studies, including 73 in one specific study, and expects to conduct additional ones. The company states that non-human primates are considered the most suitable animal model to predict human immune responses, and they completed these preclinical studies even though they were not required for FDA clearance. The ovine rumen is obtained from sheep raised for human consumption in New Zealand, which undergo veterinary inspection prior to slaughter and post-mortem carcass inspection according to USDA approved standards.

Planet-Friendly Business

TELA Bio, Inc. reported a 2023 baseline for Scope 1, 2, and 3 greenhouse gas emissions totaling 151 tCO₂e.

The company achieved a 100% waste diversion rate in 2023 by reusing all expired products in training programs. TELA Bio, Inc. has reported zero compliance violations in the last three years. The company has a stated net-zero target year of 2048.

Safe & Smart Tech

There is insufficient evidence to assess TELA Bio's alignment with the Safe & Smart Tech value. The provided article from www.fda.gov resulted in a 404 error, indicating the requested article is unavailable.

The company's core business focuses on medical devices for soft-tissue reconstruction, which has a fundamentally neutral impact on Safe & Smart Tech. The company's activities do not inherently involve high-risk technology applications like AI or extensive data collection. Given the lack of evidence, a score of 0 is assigned. The materiality analysis indicates that scores above 4 should be considered illogical without evidence of significant undisclosed activity in AI or data aggregation.

Zero Waste & Sustainable Products

TELA Bio Ltd implements several waste reduction initiatives, including using all expired products in clinical education and marketing programs to prevent waste.

For Cadaveric Training Programmes, the company ensures lab partners do not use single-use surgical equipment and procures only expired surgical equipment. The company's OviTex products are designed with over approximately 95% biologic material, with polymer fibers comprising less than 5% of the final product, or approximately 12% in OviTex LPR devices, or approximately 15% in OviTex IHR devices. The company states that reuse, resterilization, reprocessing, and/or repackaging may compromise the structural integrity of the device. OviTex products have a low recurrence rate in a clinical study, indicating good durability. The manufacturing facility in Auckland is FDA registered and ISO 13485 certified. However, in April 2018, Aroa, the manufacturer, issued a voluntary recall of resorbable OviTex products due to a reduction in labeled shelf life.